Samarth Kulkarni is the CEO and chairman of the board of CRISPR Therapeutics. He joined CRISPR as chief business officer and was appointed president and chief business officer before becoming CEO. Previously, Kulkarni was a partner at McKinsey & Company, where he had a leading role in the pharmaceutical and medical products practice. At McKinsey, he co-led the biotech practice, leading initiatives in areas such as personalized medicine and immunotherapy. Previously, Kulkarni was chairman of the board of directors of Casebia Therapeutics, a joint subsidiary of CRISPR Therapeutics and Bayer. He currently serves on the board of directors of Centessa Pharmaceuticals and two precision oncology companies, Black Diamond Therapeutics and Repare Therapeutics. He has also served on the board of the emerging companies section of the Biotechnology Innovation Organization.
Previously
History was made this year when the first FDA-approved CRISPR-based gene editing therapy became available to patients, designed to cure sickle cell anemia. That represents gr...